PanCareLIFE Study is a cohort study of patients treated for cancer in childhood, and biological case-control study nested in the cohort (WP4) is coordinated by Erasmus MC-Sophia Children's Hospital in Holland. Ensure optimal patient quality of life throughout his life is a priority for the research teams. PanCareLIFE Study also aims to identify the factors that predispose to impaired quality of life. It is in this light that will be offered to patients a quality of life questionnaires during the period of treatment and then periodically during long-term follow-up.
PanCareLIFE Study is a cohort study of patients treated for cancer in childhood, and biological case-control study nested in the cohort (WP4) is coordinated by Erasmus MC-Sophia Children's Hospital in Holland. At European level, approximately 1,200 women are expected in this latest study, the patients were already identified through certain regional or national registries in terms of cumulative doses of chemotherapy, surgery, radiation. Ensure optimal patient quality of life throughout his life is a priority for the research teams. PanCareLIFE Study also aims to identify the factors that predispose to impaired quality of life. It is in this light that will be offered to former patients to complete quality of life questionnaires during the period of treatment and then periodically during long-term follow-up. The SALTO-BIO study is the French part of the European study PanCareLIFE. CHU of Saint-Etienne as French promotor, will organize this study only on the Rhône-Alpes region (Lyon, Grenoble and Saint-Etienne centers) and will participate as co-investigator and "data provider "to WP2, WP3, WP4 and WP6. Indeed, ototoxicity is already studied by a French group.
Study Type
OBSERVATIONAL
Enrollment
101
Women will incur a blood taking to obtain fertility indication.
Chu Grenoble
Grenoble, France
IHOP 1 Lyon
Lyon, France
CH Lyon Sud
Pierre-Bénite, France
CHU Saint-Etienne
Saint-Etienne, France
Measure the FSH hormone rate.
In this arm women will incur a blood taking to measure the FSH hormone rate.
Time frame: Day 1
Measure the AMH hormone rate.
In this arm women will incur a blood taking to measure the AMH hormone rate.
Time frame: Day 1
Detect the genetic polymorphism of the FSH and AMH hormones.
With the blood taking realized for each patient, genetic markers will be obtained to identify their fertility capacity.
Time frame: Day 1
Quality of life
The quality of life for each patient will be measured with the SF-36 scale.
Time frame: Day 1
Identification of new loci associated to ovarian toxicity
With a pan-genomic method, new loci (associated to ovarian toxicity) will be identified.
Time frame: Day 1
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.